Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy ...

The cardiovascular safety of biologic therapies, including tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors, has been a subject of debate due to conflicting evidence in prior ...

SCOTCH PLAINS, N.J.--(BUSINESS WIRE)--Navigator Medicines, Inc., a clinical-stage biotech company leading the advancement of biologics ... Study of NAV-240, an anti-OX40L/TNF-alpha Bispecific ...

2 Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology RAS, Moscow, Russian Federation Objectives Neutralisation of tumour necrosis ...